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Abstract: A core component in translational cancer research is biomarker discovery using gene expression profiling for clinical tumors. 
This is often based on cell line experiments; one population is sampled for inference in another. We disclose a semisupervised workflow 
focusing on binary (switch-like, bimodal) informative genes that are likely cancer relevant, to mitigate this non-statistical problem. 
Outlier detection is a key enabling technology of the workflow, and aids in identifying the focus genes.
We compare outlier detection techniques MOST, LSOSS, COPA, ORT, OS, and t-test, using a publicly available NSCLC dataset. 
Removing genes with Gaussian distribution is computationally efficient and matches MOST particularly well, while also COPA and OS 
pick prognostically relevant genes in their top ranks. Also our stability assessment is in favour of both MOST and COPA; the latter does 
not pair well with prefiltering for non-Gaussianity, but can handle data sets lacking non-cancer cases.
We provide R code for replicating our approach or extending it.
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Introduction
Despite the limitations of cancer cell lines, there is 
widespread and increasing interest in using cell lines 
in experimental models of anticancer drug sensitivity 
to predict human clinical tumor response on the basis 
of genetic or genomic variation. This poses numerous 
challenges for rigorous data analysis and relevant data 
interpretation.1 These challenges are especially severe 
for novel agents in clinical development, where pre-
dictions are made, and potentially used, before any 
clinical response data is available.
Genes whose expression shows bimodality across 
multiple cancer data sets (this usually only happens 
within one tissue type or histology) have a strong 
potential  to  provide  useful  translatable  biomarkers 
for predictive applications in diagnostics, prognos-
tics, or predicted response to therapy. The bimodality 
provides a natural quantization, so that thresholding 
is obvious without generating a new training data set 
for each assay of interest, easing clinical assay or kit 
development as well as the use of additional   (external, 
public domain) data sets. Further, the   cancer relevance 
of  such  genes  can  stem  from  the  on/off  events—
mutation,  deletion  or    hypermethylation—that  are 
commonly  acknowledged  as  determinants  of  the 
molecular subtype. This has motivated assigning the 
name ‘Cancer Outlier Profile Analysis’ to the COPA 
algorithm2 that we include in this study.
The usefulness and cancer (or more generally dis-
ease) importance of bimodality has been recognized in 
prior work, in particular by Ertel3 but also by others.4,5 
Shiraishi5 discusses other causes in addition to muta-
tion, deletion or hypermethylation for such switch-
like behavior between alternative steady states.
Semisupervised learning presumes that the back-
ground distribution of predictor variables is relevant 
to the supervised learning task at hand, since the unla-
beled data can only inform us about the background 
distribution. Using bimodality as an indicator of can-
cer relevance matches this premise of semisupervised 
learning.  Explicitly,  detecting  bimodality  in  tumor 
gene expression profiles suggests a gene is a prime 
candidate  for  predictive  models  in  cell  lines,  for 
which we have the targeted output—the labels, such 
as  resistance  or  sensitivity  to  a  drug—determined 
experimentally. Not detecting bimodality in tumors 
suggests the gene has no relevance to cancer subtyp-
ing, and a   predictive model using it (from supervised 
learning with cell line data) will not   translate to tumors 
well. These thoughts provide the basis of the semisu-
pervised workflow we share in this manuscript. Note 
that the published semisupervised approach COXEN6 
does  not  consider  this  premise  of  semisupervised 
learning, and does in no way pursue cancer relevance 
in feature selection.
In small in vitro drug response studies focusing 
on a single histology, which typically employ on the 
order of 20 cell lines, being able to use additional 
tumor data is crucial for the discovery of useful and 
tumor  relevant  results.  Even  if  the  predictor  were 
intended for use in only cell lines, the small number 
of cases relative to number of available variables is a 
recognized problem, easily incurring ‘false positives’ 
in feature selection. However, it is now known that 
cell lines often carry ‘in vitro specific aberrations’ not 
present in tumors,7 and these need to be eliminated 
in the feature selection to discover clinically useful 
  biomarkers. These ideas are easily reduced to prac-
tice, as our workflow will show, so that the unlabeled 
tumor expression data provides a filtering scheme rel-
evant for feature selection.
Despite such potential for translational research, 
exploiting bimodal expression is more of a curiosity 
than a common routine—instead of making use of a 
few genes with switch-like behavior, published signa-
tures typically comprise tens or hundreds of mutually 
correlated genes, and use these genes to compute a 
single score to which a threshold is applied (think of 
the typical heatmaps showing a 2 by 2   checkerboard 
pattern). Considering multiple mechanisms in a redun-
dant system, we would rather expect the need of logi-
cal AND or OR operations between inputs that do not 
correlate with each other. For such approaches, the 
binary nature of bimodal expression patterns   provides 
a significant but underutilized opportunity.
To bridge the gap between needs and potential, 
we provide a practical data-driven assessment of sev-
eral alternative computational approaches to detect 
bimodal genes. For this we include various   methods to 
detect ‘outlier expression’; these are widely acknowl-
edged as cancer relevant, and bimodal genes will also 
be detected as outliers by the characterizations used 
in (deriving) these methods.
We specifically use lung cancer expression data 
published by Bhattacharjee,8 which include multiple 
histologies of NSCLC as well as normal (non-cancer, Cancer outlier discovery methods
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control) samples. With the notable exception of COPA 
the actual methods compared require the availability 
of normal cases, as they are based on having two pre-
labeled categories of cases (ie, cancer and normal).
We introduce the use of a generic test for   normality 
(Gaussianity)  as  a  fast  pre-filter,  and  examine  its 
  relation  to  rankings  from  the  other—much  slower 
to compute—methods. To our knowledge this use of 
  normality testing has not been reported previously. 
We  report  timings  indicative  of  the  computational 
cost  of  each  method,  though  these  are  specific  to 
the   implementations that we also share in additional 
files.
The test for normality (Gaussian bell shape) of the 
distribution does not require non-cancer cases, while 
the actual outlier detection methods mostly do. If only 
cancer  cases  are  available,  the  published  bimodal-
ity index4 can be used, or simply fitting mixtures of 
Gaussians with any available (typically EM) routine 
remains an option, potentially supplementing results 
from COPA. This option will definitely be quite slow 
to compute, and pre-filtering by a test for normality 
becomes all the more important. We have not included 
these parametric methods that are restricted to seeking 
only mixtures of two Gaussian shapes; such assump-
tion is very restrictive, and in practice some poten-
tially useful genes seem trimodal etc., possibly due to 
copy number variation. However, the readers will be 
able to build on our shared code and extend this work 
as desired.
For a method to be useful it should be internally 
consistent,  and  the  choice  between  methods  may 
depend  on  ease  of  use  (hampered  by  non-obvious 
parameters the user must choose) and costs of com-
putation,  implementation,  and  maintenance.  The 
quality of the results—a list of top ranked probesets 
or genes—is in our case much more difficult to quan-
tify or even assess qualitatively.
The  methods  are  here  assessed  for  their  stabil-
ity, ie, how strongly their top ranks are perturbed by 
subsampling, and for mutual concordance. If   adding 
some  experiments  (cases)  dramatically  alters  the 
results from a method, the user should have little reli-
ance on results from small experimental data sets. 
Here we equate the internal consistency of a method 
to its stability, and instead of adding experiments we 
subsample multiple times the pool of cancer cases 
available. The mutual concordance might reveal that 
a costly method can be replaced by a cheaper one, or 
that one method can replace several others. Indeed, 
we find that both of these scenarios happen here.
Our results indicate that MOST9 alone recovers the 
extreme top ranked probesets selected by the other 
methods, while in these data LSOSS10 is for all practi-
cal purposes identical to the t-test but much less effi-
cient to compute, when only viewed as a gene/feature 
selector. LSOSS does provide a split of the cancer 
cases between normal-like and outliers, while a t-test 
between non-cancer and cancer cases does not.
For the quality of the top ranked genes, we look 
for biological significance. We avoid pathway anal-
ysis on purpose, and instead resort to the available 
survival times in these data; we assess the prognostic 
relevance of some top ranked genes as individual pre-
dictors of survival. Pathway analysis relies on sets of 
genes representing the same pathway, and our prac-
tical experience is that strong bimodality—such that 
could lead to a useful biomarker with very clearly dis-
tinct states—is rare enough to not provide such gene 
sets. Also, multiple results from pathway analysis are 
difficult to compare quantitatively, so it would not (in 
its current state) provide interpretable comparisons 
between the methods.
The results of this single case study overall suggest 
that a good performer is found by combining fairly 
strict  pre-filtering  which  removes  genes  showing 
normal distribution in cancer cases, and then apply-
ing MOST. This appears to provide cancer relevant 
probesets/genes that may support biomarker discov-
ery or, more generally, cancer subtyping that could be 
informative for prognostics or drug response.
For datasets without non-cancer cases, COPA also 
provides relatively stable and cancer relevant ranking 
of features, comparable to MOST. We are unable to 
place these two methods in a rank order of prefer-
ence, but note that MOST appears to include in its 
top ranks the probesets selected by COPA; whether 
MOST adds to sensitivity or COPA gives better selec-
tivity remains undecided. However, the good match 
with ‘abnormality’ gives MOST a computational cost 
advantage when non-cancer cases are available.
While  these  results  do  suggest  some  preferences 
between the methods, we believe many readers will find 
that access to R implementations of these routines in 
attached material is particularly useful, enabling appli-
cation to other data sets and exploration of the results.Karrila et al
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To complete the picture, we briefly discuss a work-
flow, without showing results from its application, 
for  semisupervised  discovery  of  robust  predictive 
  biomarkers. By “robust” we mean that the expression 
clusters are widely separated from each other, allow-
ing inaccuracy and noise, and that translation from 
pre-clinical (often in vitro) data to tumor applications 
is at least corroborated as feasible. It is the transla-
tion step that will most easily fail without a semisu-
pervised approach, because one then tries to perform 
inference on tumors by only sampling cell lines—no 
statistical theory supports such transfer between dif-
ferent   populations. For this reason, a practical semisu-
pervised approach with the tools to make it work is 
one goal of this manuscript, and we hope others will 
find our approach useful as we have found in pro-
prietary work that cannot be shared at this time. The 
reader need not rely on our anecdotal testimony, as 
trying out the methods is fully accessible with very 
low effort.
Materials and Methods
The expression data set
The Bhattacharjee8 data set includes 139 adenocar-
cinomas and 17 normal lung samples, among other 
histologies  (squamous,  carcinoid,  and  small  cell). 
We focus on adenocarcinomas along with the normal 
cases, to demonstrate the use of bimodal expression 
indicators for subtyping within histology.
The  downloaded  expression  data  was  MAS5 
normalized  and  log2—transformed.  The  U95-Av2 
arrays initially provide expression values for 12,651 
probesets,  to  which  we  applied  a  median-absolute 
  deviation (MAD) filter to remove low-variance genes. 
  Selecting probesets with MAD . 0.7, we retained 
5900 probesets.
Pre-filtering to remove normally  
distributed probesets
To remove normally distributed probesets, we applied 
the Anderson-Darling normality test from the pack-
age nortest in R. The statistic and P-value were kept 
for future analysis.
Implementations of algorithms used
The algorithms have been implemented in R, using 
available R packages when possible and otherwise by 
coding based on the publications in the references. 
The implementations, versions, and parameters used 
are explicit in the attached material, which allows 
similar applications to other data sets in a straightfor-
ward manner.
Stability analysis
The stability of a method is here assessed through 
changes in its results during subsampling.
We create a fixed set of 1,000 subsets of the cancer 
cases, while using all of the control cases (non-cancer 
normals) in each computation. Each subset comprises 
80% of the cancer cases, and subsequently the statistics 
from all of the methods described earlier in this paper 
are computed. For each method the results from each 
computation  are  ranked,  so  that  the  most  significant 
statistic gets rank 1. These ranks are averaged over the 
1,000 samples, to generate a single average ranking of 
probesets for each method. Similarly for each method, 
the variance of the ranks of a single probeset is an indica-
tion of the stability of its rank across the 1,000 samples.
We expect the variance of the rank to depend on 
the average rank, and indeed a scatter plot on loga-
rithmic scales of these variables gives a practically 
linear result for each of the methods. A less stable 
method  will  show  a  higher  variance  than  a  more 
 s table method, at the same average rank.
Methods comparison for replaceability
The purpose of methods comparison is to show if 
some methods provide very similar average ranks for 
the top probesets, and also to potentially find some 
orderings between methods if possible. The analysis 
is exploratory in nature and done by visual assess-
ment of plots of the average ranks. The workflow of 
this methods comparison is shown in the attached 
files as Supplementary Figure S1.
To  compare  such  plots  between  different  meth-
ods, each of which has its own top ranked probe-
sets, we take top 100 probesets by average rank for 
each method, and the union across the methods. In 
this way the top ranked probesets for each method 
are included, and we can compare the average ranks 
between methods in scatter plots without any bias 
toward some ‘baseline method’.
Survival analysis
Kaplan Meier curves were plotted using the Survival 
Package in R. Logrank test P-values were computed Cancer outlier discovery methods
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between the cancer cases in the low expression and the 
high expression groups—one of these is designated 
normal-like and the other ‘outliers’. The   distinction of 
these two groups was made based on the MOST algo-
rithm which provides, for each probeset, the number 
of cases in the normal-like expression group (k-value 
in the attached code).
Results
Stability inspections
The stability of the methods is compared graphically 
in Figure 1. The top 100 probesets are included for 
each method, and log10 of the standard deviation is 
plotted against log10 of the average rank. ORT11 and 
OS12 consistently show a higher variance than the rest 
of the methods, so the other methods are preferred if 
stability is emphasized due to a small number of cases. 
Note that for some top ranked probesets, around aver-
age rank 10, ORT shows exceptionally high variances 
of the rank—this method appears, in this sense, worse 
performing than OS in these data.
Due to the population of subsamples being held 
constant, the different methods are fairly compared—
superiority or inferiority does not stem from different 
subsamples between methods. Also, with 1,000 ran-
dom subsamples, the numerical estimates of average 
rank and variance are not an artifact of the selection of 
subsamples. The consistent linear trends in   Figure 1 
corroborate that our analysis approach produces rea-
sonable and consistent results.
The  nearly  linear  relation  in  a  log-log  plot  of 
  variance to average rank suggests a power law depen-
dence of variance on rank. The methods with a steeper 
slope have a higher exponent in the power law. Such 
an approximation of the variance could be useful for 
someone interested in deriving statistical confidence 
bounds or such by semi-analytic methods.
Correlations between different algorithms
The matrix of scatterplots in Figure 2 allows explor-
ing the similarities and differences of the methods by 
visual exploration of the union of top 100 from each 
method.
The  LSOSS  and  TTEST  methods  are  almost 
  identical; LSOSS is a variation of the t-test. Both COPA 
and OS methods appear to be strongly negatively cor-
related to the t-test (TTEST); COPA and OS seek outli-
ers that subdivide the cancer cases to normal-like and 
normal-unlike, while t-test gives highest scores when 
all the cancer cases separate well from the non-cancer 
control cases. However, also t-test can rank highly some 
probesets that are useful for cancer vs. cancer subtyp-
ing, according to our practical analysis experience.
Interestingly,  MOST  appears  to  incorporate  the 
sensitivities  of  the  other  outlier  detection  methods 
including  also  the  t-test  based  methods.  In  other 
words,  when  any  other  method  ranks  a  probeset 
among, say, the top 10, then the probeset is highly 
ranked also by MOST. Graphically, in the top row of 
Figure 2, points close to left edge are also close to 
the bottom of the scatterplots—the top left-hand-side 
corners are empty. Only the row with ORT—which 
was less stable—also shows empty top LHS corners, 
but it appears noisy in the correlations for the top 
ranked probesets.
Anderson-Darling normality filtering
This  is  a  rather  unusual  prefiltering—we  know  of 
no  prior  report  on  removing  normally  distributed 
variables by pre-filtering—but here well motivated. 
Probesets showing an expression pattern with two or 
more peaks cannot possibly be well fit with a single 
normal distribution, therefore removing the cases with 
a good fit does no harm on seeking bimodals (with no 
requirement of mixing two Gaussians imposed). This 
provides the opportunity, while the motivation comes 
from  the  computational  expense  of  several  of  the 
methods we compare, discussed in more detail later. 
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Figure 1. Stability of methods. At any given average rank, OrT and 
OS  methods  have  similar  variance  of  the  probeset’s  ranks  across 
  subsamples. The remaining methods cluster together at a lower   variance, 
showing better stability across the subsamples.Karrila et al
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As there is wide interest in the normality of a distri-
bution of, say, the error residuals in statistical model 
fitting, we   correctly expected that the available tests 
for Gaussian distribution would be well-developed 
and fast to compute.   Particularly costly pre-filtering 
would make little sense.
In Figure 3 the blue squares for MOST are bound 
below  by  a  straight  line,  such  that  approximately 
x = y + 0.5 on the logarithmic scales shown. This 
means that if we want Y top probesets from MOST, 
we can pre-filter to keep only about 3*Y probesets 
with the fast AD normality score. Such a rule likely 
depends on the dataset, but the observation is encour-
aging and suggests that, for example, with some other 
given  dataset,  keeping  only  the  top  500  probesets 
based on AD scores does little harm to finding the top 
about 150 probesets for MOST—and the most inter-
esting top 20 are probably all retained. The effect on 
computational cost is significant,   making fairly large 
problems feasible on a conventional laptop.
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Figure 2. Pairs plot. The matrix of scatter plots illustrates dependencies between the different outlier measures. The scales of average ranks are again 
logarithmic, giving more relative emphasis to the top ranks. LSOSS is practically equivalent to t-test, providing for the top ranks exactly the same rank 
order. Note that a top rank from COPA implies a good rank also from MOST; the same goes for OS and t-test also, so MOST consolidates the sensitivity 
of several other methods.Cancer outlier discovery methods
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The other methods do not allow as strict   pre-filtering 
by AD scores—the lower bounding straight lines for 
these methods have lower slopes than the line for 
MOST. Therefore MOST seems to match prefilter-
ing by AD normality score particularly well, possibly 
enabling very efficient computations for this general 
type of problems.
We have consciously avoided comparisons based 
on simulated datasets, whose clear advantage is that 
‘everything is known’ about them, while they may be 
completely unrealistic. However, for the computation 
times we choose to use such data, and the code for 
generating it is included in case a reader wishes to 
pursue further comparisons with similar datasets.
An artificial dataset of mixed Gaussian   distributions 
was computationally generated to simulate 40 samples 
(20 normals, 20 cancer cases) and used to   determine 
average  computation  times  on  a  Windows    Intel 
  Notebook Machine with 2GB of RAM. The overall 
trends in Figure 4 show that the computation time   versus 
number of probesets increases linearly. In general, these 
computations are fairly quick and can be   conducted on 
a notebook. The largest Affymetrix mRNA   platform 
(U133plus2) has about 55,000 probesets and at most 
35,000 probesets remain after some mild conventional 
pre-filtering  based  on  our  experience.  We  estimate 
that  the  outlier  computations  should  then  take  less 
than 1 minute on a Windows Machine. However with 
a larger number of cases, such as in the dataset by 
Bhattacharjee, both the memory and speed limitations 
will encourage the use of parallel processing.
Survival analysis
The  ultimate  goal  of  selecting  bimodal—or  more 
generally outlier—genes is to find useful candidate 
biomarkers that are cancer relevant. We perform a 
data-driven evaluation, using the survival data pro-
vided by Bhattacharjee.
We collected the top 6 probesets identified by each 
method, to a total of 19 probesets. Only 3 of these 
meet the following criteria based on survival   analysis: 
i) There are more than 2 samples in each arm of the 
Kaplan Meier plots ii) The Logrank P-value , 0.1 
ensuring statistical significance.
The Kaplan-Meier plots for these three probesets 
are shown in Figure 5. Note that the survival analy-
sis used is somewhat naïve and basic, only assess-
ing individual probesets and not their combinations. 
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The results from this analysis do not allow quanti-
tative comparison of the methods, but indicate rel-
evance to cancer subtyping based on the top genes/
probesets recovered.
ASCL1  and  CALCA  were  identified  in  the  top 
6 genes as ranked by both MOST and COPA, while 
these genes and also INHA were identified among the 
top 6 by OS. Interestingly, the gene INHA was among 
the top 20 from both MOST and COPA.
ORT, LSOSS and TTEST had none of the above 
mentioned  genes  in  the  top  6—they  were  ranked 
many orders lower. So a simplistic survival analysis 
corroborates the cancer relevance of MOST, COPA 
and OS over the other methods tested, in these par-
ticular data.
The identified genes have strong survival signifi-
cance by log rank test, and play important roles in 
cancer. ASCL1 is a pivotal member of the NOTCH 
pathway  with  known13  clinical  relevance  in  pros-
tate cancer. High expression of the gene inhibits the 
NOTCH signaling formation, allowing tumors to rap-
idly develop and progressively advance the   disease.14 
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Table 1. List of top 6 probesets from MOST and their average log ranks for all of the methods tested.
MOsT LsOss cOpA ORT Os TTesT genes genenames
40544_g_at 0.119 3.181 0.192 1.711 0.087 3.147 ASCL1 achaete-scute complex 
homolog 1 (Drosophila)
37741_at 0.372 0.005 3.614 0.301 3.428 0.005 PYCr1 pyrroline-5-carboxylate 
reductase 1
36299_at 0.593 3.246 0.848 1.939 0.409 3.213 CALCA calcitonin-related 
polypeptide alpha
37019_at 0.639 3.107 0.178 1.434 0.491 3.141 FgB fibrinogen beta chain
39052_at 0.777 3.286 2.490 2.376 1.177 3.258 KrT14 keratin 14
34342_s_at 0.837 0.300 3.553 1.082 3.657 0.300 SPP1 secreted phosphoprotein 1
Similarly,15  high  expression  of  Calcitonin-alpha 
(CALCA) results in high Ca2+ serum levels or hyper-
calcaemia, a condition which is strongly associated 
with tumor malignancy and poor 1-year survival rates 
of 10%–30%. Elevated levels of Inhibin drive pros-
tate tumors into a pro-tumorigenic and pro-metastatic 
state16 and it is also a well-known marker17 for granu-
losa-cell tumors.
These three genes received average ranks of order 
10∧3 by LSOSS and TTEST (see Table 1),   suggesting 
that these methods are possibly suitable for finding 
diagnostic markers of cancer, but not necessarily for 
finding markers to discover subtypes of cancer cases.
A semisupervised workflow for  
discovering robust translatable  
biomarkers
In the semisupervised setting for predicting   clinical 
response we typically have labeled cell line data, with 
the label indicating eg, sensitivity or resistance, and 
basal  (pre-treatment)  mRNA  expression    values  for 
these cell lines that we hope can predict the response to 
treatment. Unlabeled data is provided by basal expres-
sion values for clinical tumor samples, for which we 
usually have no information about   sensitivity or resis-
tance to the experimental drug under study (though 
survival under standard of care may be known). Our 
goal is to use both datasets to learn basal expression 
based predictors of sensitivity. The following steps 
seem to provide, at least on occasion, plausible can-
didate  markers  and  predictors;  although  all  of  our 
results from this approach currently lack published 
clinical validation and are proprietary in nature.
The approach though has been published as a poster 
in Frontiers in Cancer Science, Singapore 2010, with 
a more detailed discussion than space allows here. 
Here we wish to share our approach, which strongly 
depends on the bimodality of biomarkers; it provides 
a natural application to outlier detection methods.
1. Use supervised training to select individually infor-
mative  genes  that  allow  robust  thresholding,  ie, 
slack in threshold location. The slack is calculated 
under constraining sensitivity and specificity limits. 
Most probesets do not satisfy these constraints at 
all, the remaining ones are ranked by the slack and 
a short ‘top ranked’ list is retained. A suitable Java 
software tool has been published,18 and we recom-
mend requiring (sensitivity, selectivity) = (0.9, 0.4) 
and repeating the calculation with (0.4, 0.9). The 
two lists are joined, and the ‘margin’ from the Java 
program is typically required to exceed 1 or 2 in 
log2—transformed expression scale. Note that in 
particular bimodal genes allow moving the thresh-
old between the two clusters, with little effect on 
the split of cases—the sensitivity and selectivity are 
then almost constant, so such genes/probesets will 
allow a large ‘margin’ and are picked by Pinese’s 
approach18 if they are informative.
2. Use  an  unsupervised  check  to  refine  this  short 
list, picking genes that also in tumors show easy/
robust thresholding (ie, cluster based quantization, 
or bimodal expression without any requirement for 
Gaussian shapes). This retains only genes relevant 
to the molecular subtyping of tumors, eliminating 
in vitro -specific aberrations.7 Now, predictors that 
take  as  inputs  quantized  (binary)  values,  learned 
from the labeled data, can be applied to the unlabeled 
data since similar quantization is enabled there.
The  unlabeled  data  has  contributed  to  feature 
selection, and if we had a list of its bimodal genes, 
we could only use these probesets in the supervised Karrila et al
118  Cancer Informatics 2011:10
feature selection of step 1 and skip step 2. In our early 
applications,  the  short  list  from  supervised  feature 
selection was manually checked for bimodality in the 
unlabeled tumor data—often in multiple datasets.
3. Create predictor(s) from the labeled data using the 
binarized input features selected above. 
4. Apply predictor(s) to unlabeled data, whether the 
same as used above or different, based on expression 
quantization from cluster patterns of   expression. 
The cluster pattern for each gene should translate 
to a low/high binary value that is used as input to 
the predictor. Each application of a predictor gives 
an estimate of eg, responder prevalence.
Our approach nurtures the clinical tumor relevance 
of the biomarker candidates, ensures that in vitro spe-
cific aberrations are not used as predictors, and that 
prevalence estimates can be computed from available 
tumor data to assess the clinical need for biomark-
ers and predictors. Further, it leads to small predictors 
with few inputs that may use logical AND and OR 
operations with binarized (Boolean) inputs, and that 
facilitate use of other types of assays with the natural 
thresholding of expression patterns.
This approach addresses in a simple and doable way 
a problem that is not covered by statistics:   sampling one 
population (cell lines) to perform inference in a differ-
ent population (tumors), by making use of tumor rele-
vant data before predictors are constructed. We suggest 
that on doing this type of inference with semisupervised 
tools,  one  should  avoid  giving  confidence  P-values 
with predictions, as they would suggest that the prob-
lem conforms to the requirements of statistical theory.
This brief discussion of semisupervised methodol-
ogy serves as a significant motivation for the pursuit 
of outlier or bimodality analyses, and clearly links 
these tools to personalized medicine and translational 
oncology.
conclusions
We have provided a reproducible comparison of a set 
of methods available for detecting outliers, including 
bimodal genes, with attached code that allows re-use 
also in other contexts. A single NSCLC data set which 
includes some non-cancer cases was used in the data-
driven assessment.
The importance of this study may be less in the 
results, and more in supporting a wider use of bimodal 
genes  in  biomarker  applications  by    sharing  code, 
assessment methods, and a semisupervised workflow. 
Bimodality is an indication of cancer relevance, it 
provides natural thresholding and binarization that is 
robust against normalization and scaling effects, and 
can even carry over between different types of assay 
in a very   convenient way.
As  for  the  results,  the  timing  and  other  results 
clearly  indicate  that  pre-filtering  with  a  score  to 
remove  probesets  with  (near)  Gaussian  expression 
distribution  is  numerically  efficient  and  couples 
especially well with the MOST method for outlier 
  detection. As MOST is also sensitive to top ranked 
genes by the other methods tested, it appears a use-
ful overall performer. While our results from use of 
a single dataset can only be indicative, we consider 
such indications much more proper than those from 
simulated data. A typical flaw in such simulations is 
a ‘forced’ shape of distributions, eg, only creating 
mixtures of Gaussians—real expression data does not 
conform to such restrictions.
The stability results also favor MOST, positioned 
in the more stable cluster across all of the methods, 
while computational cost of MOST is on par with 
other outlier detection methods. We have also shown 
that a few of the top ranked probesets from MOST, 
in these data, include prognostically significant and 
therefore  cancer  relevant  probesets.  We  have  not 
evaluated the biological significance of the rankings 
by any other means.
Partly due to the fortunate interplay with filter-
ing  based  on  Gaussianity  of  the  expression  dis-
tribution across cancer cases, as well as the other 
observations  above,  our  recommendation  is  to 
use  MOST  in  combination  with  pre-filtering  by 
the   Anderson-Darling normality test, especially if 
speed of execution is essential. However, if time 
and other resources allow, the application of also 
other outlier detection methods will probably pro-
vide more comprehensive results—the other meth-
ods appear not compatible with strict pre-filtering 
by the normality test.
Aside from COPA, this comparison has not cov-
ered outlier detection or bimodality scoring methods 
that can be used with only cancer cases—the other 
methods we have covered require access to a set of 
non-cancer cases of the same tissue type. The current 
study could also be extended to cover more datasets, Cancer outlier discovery methods
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but we feel it serves its purpose by sharing a set of 
tools and instructing in their use.
Despite  its  simplicity  and  comparatively 
low computational cost on par with MOST (not 
  taking  into  account  prefiltering  options),  COPA 
is  a  good  performer;  it  is  comparatively  stable 
and  ranked  highly  the  genes  with  prognostic 
value  that  we  found  among  top  ranks  from  any 
of the   methods. Our assessment of survival also 
  corroborated OS among the top performers to pick 
  prognostic genes.
We included a simple but little known semisuper-
vised approach that may be original and novel (aside 
from our prior publication as a poster) for predic-
tive  biomarker  discovery  from  combined  cell  line 
and tumor expression data, with the labels (eg, resis-
tant or sensitive) known only for cell lines. With our 
approach, relevance to tumors is favored and clinical 
assay development is facilitated by bimodal naturally 
thresholded expression patterns. This approach high-
lights the practical importance in translational oncol-
ogy research of tools for detection of outliers and 
especially bimodality, and addresses the problem of 
sampling cell lines while doing inference in tumors; 
a  type  of  problem  outside  the  realm  of  statistical 
theories.
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For each
method
K
Prepare test data for J = 1,…,1000
Normal
cases
Cancer
cases
Random subsamples
J = 1,…,1000
Compute comparison measures
Average rank is 
AIK = AVE(RIJ, all J)
Variance of rank is
VIK = VAR(RIJ, all J)
Significance 
for gene I is PIJ
Rank of gene I
is RIJ
Tally gene I vs. method K tables
VIK AIK
Figure s1 Workflow of methods comparison and stability analysis for 
expression outliers and bimodality.
supplementary Data
A self-extracting archive of the R-code, with some 
sample output.
CI_outlier_detection_R.zip
LOG_AVERAGE_RANKS.xls
LOG_STDDEV.xls